Current Status of Immunotherapy for Lung Cancer and Future Perspectives / 결핵
Tuberculosis and Respiratory Diseases
;
: 14-19, 2020.
Article
in English
| WPRIM
| ID: wpr-782226
ABSTRACT
Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors, new therapeutic strategies are needed to improve clinical outcomes. Immunotherapy through the use of immune checkpoint inhibitors has provided one of the most important breakthroughs in the management of solid tumors, including lung cancers, and has shown promising results in numerous clinical trials. This review will present the current status of immunotherapy for lung cancer and future perspectives on these treatments.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phosphotransferases
/
Prognosis
/
Protein-Tyrosine Kinases
/
ErbB Receptors
/
Immunotherapy
/
Lung
/
Lung Neoplasms
/
Lymphoma
Type of study:
Prognostic study
Language:
English
Journal:
Tuberculosis and Respiratory Diseases
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS